Cargando…
Phase II Evaluation of VDC‐1101 in Canine Cutaneous T‐Cell Lymphoma
BACKGROUND: Canine cutaneous T‐cell lymphoma (CTCL) is an uncommon disease for which efficacious therapies are lacking. The novel anticancer nucleotide prodrug VDC‐1101 (formerly known as GS‐9219) has shown efficacy in dogs with multicentric lymphoma. One of the observed adverse effects with this dr...
Autores principales: | Morges, M.A., Burton, J.H., Saba, C.F., Vail, D.M., Burgess, K.E., Thamm, D.H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895598/ https://www.ncbi.nlm.nih.gov/pubmed/25274443 http://dx.doi.org/10.1111/jvim.12429 |
Ejemplares similares
-
GS-9219/VDC-1101 - a prodrug of the acyclic nucleotide PMEG has antitumor activity inspontaneous canine multiple myeloma
por: Thamm, Douglas H, et al.
Publicado: (2014) -
Comparison of Carboplatin and Doxorubicin‐Based Chemotherapy Protocols in 470 Dogs after Amputation for Treatment of Appendicular Osteosarcoma
por: Selmic, L.E., et al.
Publicado: (2014) -
Gammaherpesviruses and canine lymphoma: no evidence for direct involvement in commonly occurring lymphomas
por: Waugh, Elspeth M., et al.
Publicado: (2015) -
Canine T‐Zone Lymphoma: Unique Immunophenotypic Features, Outcome, and Population Characteristics
por: Seelig, D.M., et al.
Publicado: (2014) -
Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma
por: Thamm, D.H., et al.
Publicado: (2017)